Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Cardiol. Feb 26, 2025; 17(2): 99074
Published online Feb 26, 2025. doi: 10.4330/wjc.v17.i2.99074
Table 1 Baseline demographic and clinical characteristics, n (%)
Characteristics
Patients with STEMI (n = 55)
Mean age, years54
Gender
Male39 (70.9)
Female16 (29.1)
Diagnosis
AWMI34 (61.8)
IWMI + PWMI12 (21.8)
LWMI1 (1.8)
IWMI + RVMI8 (14.5)
Risk factor
DM10 (18.2)
HTN9 (16.4)
Tobacco chewers13 (23.6)
LVEF at admission
< 409 (16.4)
40-5032 (58.2)
≥ 5014 (25.5)
Mean LVEF, %44.2
LV systolic dysfunction at the time of presentation, %74.6
Time of presentation to hospital in hours
0-1221 (38.2)
12.1-2421 (38.2)
24.1-489 (16.4)
Above 484 (7.3)
Thrombolysis
Yes21 (38.2)
No34 (61.8)
Killip class
I31 (60)
II14 (28)
III5 (10)
IV1 (2)
History
Prior MI8 (16)
CABG4 (8)
Mean heart rate, beats/minute90
Mean SBP, mm Hg106
Mean DBP, mm Hg70
Mean eGFR, mL/min60.2
Table 2 Angiographic data and treatment profile, n (%)
Characteristics
Patients with STEMI
P value
Culprit artery
LAD34 (61.8)
LCX7 (12.7)
RCA14 (25.5)
First angiogramSecond angiogram
Thrombus grade0.127
Grade 00 (0)30 (55.6)
Grade 10 (0)13 (24.1)
Grade 210 (18.2)9 (16.7)
Grade 318 (32.7)2 (3.7)
Grade 418 (32.7)0 (0)
Grade 59 (16.4)0 (0)
Myocardial blush grade0.179
Grade 00 (0)0 (0)
Grade 121 (38.2)0 (0)
Grade 230 (54.5)20 (37)
Grade 34 (7.3)34 (63)
TIMI flow grade0.699
01 (1.8)0 (0)
13 (5.5)0 (0)
232 (58.2)2 (3.7)
319 (34.5)52 (96.3)
Culprit artery stenosis
< 70%7 (12.73)23 (42.59)
70%-95%30 (54.55)21 (38.89)
95%-99%18 (32.73)10 (18.52)
Culprit artery diameter, mm
mean ± SD2.94 ± 0.293.13 ± 0.31
Median (range)3.00 (2.25-3.50)3.00 (2.25-3.50)
POBA/thrombosuction
Yes4 (7.3)
No51 (92.7)
LMWH
Yes55 (100)
No0 (0)
GP IIb/IIIa inhibitors
Yes21 (38.2)
No34 (61.8)
Table 3 Procedural outcomes and intraprocedural complications of deferred stenting, n (%)
Characteristics
Patients with STEMI
Procedural outcomes for all patients
Hospital course
Uneventful33 (60)
AF1 (1.8)
CHB3 (5.4)
Death1 (1.8)
Hypotension8 (14.5)
LVF5 (9)
LVF, AF2 (3.6)
VT2 (3.6)
Intraprocedural complications in patients with deferred stenting
No complications46 (85.19)
Slow/no-reflow after PCI
Slow-reflow4 (7.41)
No-reflow4 (7.41)
No46 (85.19)
MACE
Bradycardia1 (1.85)
CHB1 (1.85)
Hypotension4 (7.41)
LVF1 (1.85)
VT1 (1.85)